Company news

TScan Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer

January 28, 2024

TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR

January 17, 2024

TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress

January 3, 2024

TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition

December 8, 2023

TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations

December 6, 2023

TScan Therapeutics Expands Manufacturing Leadership with the Appointment of Justin McCue, Ph.D., as Chief Technology Officer

December 3, 2023

TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 8, 2023

TScan Therapeutics Announces Upcoming Presentation at the 65th American Society of Hematology Annual Meeting and Exposition

November 1, 2023

TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAME

August 28, 2023

TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

August 9, 2023

TScan Therapeutics Announces Transition of Chief Financial Officer

June 28, 2023

TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-200-A0201 Targeting HPV16 to Treat Solid Tumors

June 5, 2023

TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the 2023 American Society of Clinical Oncology Annual Meeting

May 31, 2023

TScan Therapeutics Announces Pricing of $140 Million Public Offering

May 25, 2023

TScan Therapeutics Announces Launch of Proposed Public Offering

May 24, 2023

TScan Therapeutics Appoints Gavin MacBeath, Ph.D. as Chief Executive Officer and as a Member of the Board of Directors

May 23, 2023

TScan Therapeutics Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting

May 16, 2023

TScan Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 9, 2023

TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the American Society of Gene and Cell Therapy 26th Annual Meeting

May 1, 2023

TScan Therapeutics Announces Appointment of Barbara Klencke, M.D., to its Board of Directors

April 9, 2023

TScan Therapeutics Announces CEO Transition

March 30, 2023

TScan Therapeutics Announces First Patient Dosed in Phase 1 Umbrella Clinical Trial Evaluating TSC-100 and TSC-101 for the Treatment of Hematologic Malignancies

March 13, 2023

TScan Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Upcoming Milestones

March 7, 2023

TScan Therapeutics Announces Presentation at the H.C. Wainwright Cell Therapy Virtual Conference

February 20, 2023

TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors

January 22, 2023

TScan Therapeutics Announces 2023 Clinical Plans and Highlights Recent Progress

January 4, 2023

TScan Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

November 8, 2022

TScan Therapeutics Announces Upcoming Virtual Investor Event

November 6, 2022

TScan Therapeutics Announces Upcoming Poster Presentation at the 64th American Society of Hematology Annual Meeting and Exposition

November 2, 2022

TScan Therapeutics Announces Upcoming Poster Presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting

October 4, 2022

TScan Therapeutics Secures Convertible Debt Facility for up to $60 Million with K2 HealthVentures

September 11, 2022

TScan Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Progress

August 9, 2022

TScan Therapeutics Announces Publication in Cell Highlighting the Discovery of Tumor Antigens and TCRs for the Treatment of Solid Tumors Using Foundational Screening Technology

July 10, 2022

TScan Therapeutics Appoints Debora Barton, M.D., as Chief Medical Officer

July 6, 2022

TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-101 for the Treatment of Hematologic Malignancies

May 30, 2022

TScan Therapeutics Announces Upcoming Presentations at the 25th American Society of Gene and Cell Therapy Annual Meeting

May 1, 2022

TScan Therapeutics Appoints Leiden Dworak, CPA, MBA, as Vice President, Finance

April 10, 2022

TScan Therapeutics Reports Full Year 2021 Financial Results and Highlights Key 2022 Priorities

March 8, 2022

TScan Therapeutics Announces Presentation at the 11th Annual SVB Leerink Global Healthcare Conference

February 9, 2022

TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-100 for the Treatment of Hematologic Malignancies

January 23, 2022

TScan Outlines 2022 Priorities as Programs Enter Clinic

January 9, 2022

TScan Therapeutics Announces Poster Presentations at the 63rd American Society of Hematology Annual Meeting and Exposition

December 12, 2021

TScan Therapeutics Establishes Facility to Manufacture T Cell Receptor Engineered T Cell Therapies

December 1, 2021

TScan Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress

November 9, 2021

TScan Therapeutics Announces Upcoming Presentations at the 63rd American Society of Hematology Annual Meeting and Exposition

November 3, 2021

TScan Therapeutics Appoints Heather Savelle as Vice President, Investor Relations

October 4, 2021

TScan Therapeutics Appoints Zoran Zdraveski, J.D., Ph.D. as Chief Legal Officer

September 8, 2021

TScan Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress

August 18, 2021

TScan Therapeutics, Inc. Announces Pricing of Initial Public Offering

July 14, 2021

← Newer news releases

Decks

The 5 newest of 13 decks. Every deck is listed under its year.